Ultrahuman Adds Glucose Tracking Through Abbott Partnership

The smart ring maker is integrating Abbott’s Lingo over-the-counter CGM as glucose data becomes a key new frontier in connected wellness

Smart ring maker Ultrahuman is bringing its metabolic health platform further into the U.S. market with the launch of M2 Live, a new glucose-tracking product that integrates data from Abbott’s Lingo over-the-counter continuous glucose monitor (CGM).

The launch makes Ultrahuman one of the first platforms to integrate with Lingo, Abbott’s CGM for adults who are not on insulin and want to better understand their overall health and wellness, including those with prediabetes. M2 Live doesn’t require a prescription, and pricing starts at $99 per month on subscription.

For Ultrahuman, the launch is part of a broader attempt to build a preventive health ecosystem around real-time data. The company is best known for its smart ring, but over the past year it has pushed deeper into blood testing, AI-powered health interpretation, workout personalization and clinical-style insights.

In October, Ultrahuman launched Vision Cloud, a free tool that allows users to upload medical test results and receive AI-generated summaries, long-term health trends and personalized recommendations. At the same time, the company introduced Blood Vision Essentials, a $99 blood-testing panel covering more than 60 biomarkers across areas including metabolism, cardiovascular health, thyroid function, immunity and liver health.

Ultrahuman is trying to differentiate itself by connecting multiple layers of data rather than presenting glucose in isolation. M2 Live can be used on its own through the Ultrahuman app, but the company is positioning it as most useful when paired with the Ultrahuman Ring and Blood Vision. Its Jade AI system connects glucose patterns with sleep, HRV, activity, stress, recovery and skin temperature, while Blood Vision adds more than 100 blood biomarkers for users on the company’s higher-tier testing plans.

“Ultrahuman created an entirely new category: glucose monitoring for wellness,” said Ultrahuman founder and CEO Mohit Kumar. “By combining M2 Live with glucose data from Abbott’s Lingo, people can better understand how to make healthy change and improve their metabolic health.”

The platform includes Ultrahuman’s Metabolic Score, a daily 0-to-100 score designed to reflect glucose regulation, along with spike detection, food scoring and fueling insights for exercise. It also includes OGDb, Ultrahuman’s open glucose database, which shows anonymized average glucose responses from users for different foods.

“For our U.S. customers, the over-the-counter solution with Lingo means Ultrahuman M2 Live removes the friction of needing a physician for people to access their glucose data and insights,” said Hussain Ahamed, who leads strategic partnerships in the Americas for Ultrahuman.

The U.S. launch also comes after a complicated stretch for Ultrahuman in the American market, although things may be looking up.

Earlier this year, the company reopened U.S. pre-orders for its Ring Pro after resolving import restrictions tied to an International Trade Commission patent dispute involving Oura. That re-entry gave Ultrahuman another chance to compete in the fast-growing smart ring category in America, where Oura remains the dominant player and newer entrants are trying to win on price, battery life, subscriptions and ecosystem strategy.

The launch also reflects a larger shift in the wellness market. Glucose tracking was once largely confined to diabetes care, then became popular among biohackers and elite performance consumers. Now, with over-the-counter CGMs entering the market, glucose data is being positioned for a wider audience interested in weight management, energy, focus, sleep and longevity.

M2 Live will launch in the U.S. through Ultrahuman’s website in the coming weeks. A single sensor costs $129, while the monthly subscription starts at $99. Each Lingo biosensor can be worn for up to 14 days.